BridgeBio announced that the Palo Alto, Calif.-based biopharmaceutical company signed an exclusive deal with Bristol Myers Squibb to develop and commercialize a potential treatment for cancer.
Pfizer and Ionis Pharmaceuticals announced that the former is abandoning the vupanorsen program for cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG), or high triglycerides. Pfizer was leading the program.
South Korean biotechnology firm ABL Biotechnologies signed a global licensing and exclusive collaboration agreement with Sanofi to develop and commercialize a new therapy candidate for Parkinson’s disease.
Shares of Flexion Therapeutics soared in trading on Oct. 11 after Pacira Biosciences announced the acquisition of the Burlington, Massachusetts-based biopharmaceutical company for $427 million in cash.
Avantor will buy Masterflex from privately held Antylia Scientific in a $2.9 billion all-cash deal to beef up the U.S. lab products provider’s Covid-19 therapy and vaccine manufacturing operations.
Shoreline Biosciences is developing an off-the-shelf, targeted, allogeneic approach to natural killer (NK) and macrophage cell therapies which the immunotherapy company’s chairman and CEO believes is one-of-a-kind.
One month after GlaxoSmithKline outlined plans for the company’s future following a planned split between its pharmaceuticals and consumer health businesses, GSK posted second-quarter 2021 sales of £8.1 billion ($11.2 billion).
In PerkinElmer’s largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy the biomedical research tool company BioLegend.
Endo International Plc agreed to pay $35 million to settle a lawsuit by Tennessee local governments and on behalf of a child allegedly born addicted to painkillers accusing the drugmaker of fueling the opioid epidemic, the company announced July 22.
Indianapolis-based Eli Lilly and Company is acquiring Pasadena, Calif.-based Protomer Technologies in a deal that may exceed $1 billion.